PPARG and obesity disorder: In a mouse model of obesity, treatment with 1% fucoidan suppressed adiposity by transcriptionally inhibiting the expression of aP2 and PPAR-γ as well as inhibiting acetyl-CoA carboxylase activity, thereby decreasing fatty acid synthesis [36].